Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Strategy lagged the Russell Midcap® Growth Index in the fourth quarter due to stock selection. The performance was in line with expectations for the full year. The firm believes […]
Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Strategy lagged the Russell Midcap® Growth Index in the fourth quarter due to stock selection. The performance was in line with expectations for the full year. The firm believes […]
Gorman-Rupp (GRC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Gorman-Rupp (GRC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
KB Home could gain as the homebuilder reorients its corporate strategy around more profitable build-to-order houses, according to Citizens JMP Securities. The investment bank began research coverage of KB Home with a market outperform rating, and a 12-month price target of $77, suggesting roughly 45% upside. "We see the shares as undervalued at current levels," Citizens analyst James McCanless II ...
KB Home could gain as the homebuilder reorients its corporate strategy around more profitable build-to-order houses, according to Citizens JMP Securities. The investment bank began research coverage of KB Home with a market outperform rating, and a 12-month price target of $77, suggesting roughly 45% upside. "We see the shares as undervalued at current levels," Citizens analyst James McCanless II wrote Tuesday in a 25-page report. "KB is shifting the product mix back toward to-be-built homes, which should be a long-term gross margin tailwind." KB Home had largely focused on build-to-order (BTO) construction for most of its history, accounting for roughly 70% of sales versus 30% for speculative homes. But the company shifted its focus toward spec homes in the re-housing boom during the Covid-19 pandemic. Spec homes, or houses that builders themselves design and construct, generally command smaller profits than their build-to-order counterparts. "BTO demand has improved recently and KB plans to lean into that demand because BTO homes typically have a higher gross margin than spec homes," McCanless wrote. Other tailwinds include KB's operations in California, where "existing competition is muted in most markets," and a potential rebound in gross profit margins in the fiscal year ending Nov. 30, 2027. The Citizens call is contrarian. Of the 17 analysts covering KB Home on Wall Street, only three rate it a buy, LSEG data shows. Eleven have a hold on the stock and three an underperform or sell rating. The average price target on KB Home shares is $60, suggesting 13% upside. KB Home shares have fallen 18% in the past month while the S & P 500 is down 4.5% and the iShares U.S. Home Construction ETF by 17%.
monsitj Cantor Fitzgerald struck a cautiously optimistic tone in its latest bi-weekly macro trading report, arguing that recent market weakness may offer a compelling medium-term entry point for investors. The firm highlighted that while geopolitical tensions in the Middle East—particularly involving the U.S., Israel, and Iran—introduce near-term uncertainty, the underlying economic backdrop remai...
monsitj Cantor Fitzgerald struck a cautiously optimistic tone in its latest bi-weekly macro trading report, arguing that recent market weakness may offer a compelling medium-term entry point for investors. The firm highlighted that while geopolitical tensions in the Middle East—particularly involving the U.S., Israel, and Iran—introduce near-term uncertainty, the underlying economic backdrop remains resilient. Corporate earnings and broader economic conditions, it noted, appear sufficiently strong to absorb potential short-term disruptions tied to the conflict. Despite this constructive outlook, Cantor Fitzgerald emphasized that risks remain elevated, with a wide range of possible outcomes depending on how the situation unfolds. As such, investors should not assume a clear trajectory in the near term. Importantly, the report points to a sharp shift in market positioning and sentiment. Institutional investors have significantly reduced risk exposure, and valuation multiples have contracted meaningfully. While the S&P 500 has declined roughly 6% from its peak, forward price-to-earnings ratios have fallen by approximately 14%, signaling deeper underlying caution. Market Tracking ETFs: ( DIA ), ( DDM ), ( DOG ), ( DXD ), ( SDOW ), ( SPY ), ( VOO ), ( IVV ), ( RSP ), ( SSO ), ( UPRO ), ( SH ), ( SDS ), ( SPXU ), ( QQQ ), ( QQQM ), ( TQQQ ), ( QID ), and ( SQQQ ). More on markets The AI Bubble Is Going To Burst Sector breakdown since the start of the U.S.–Iran conflict: Energy leads, materials lags Treasury yields spike as markets reprice Fed rate hike possibility Bearish sentiment tops 50% as AAII survey signals sharp investor shift S&P 500 slides but these 15 stocks remain overbought
Kwangmoozaa/iStock via Getty Images Last Wednesday , Johnson & Johnson ( JNJ ) announced that the FDA had approved Icotyde, a once-daily oral peptide for the treatment of plaque psoriasis. This drug selectively blocks the interleukin-23 receptor (IL-23) and was a joint discovery with Protagonist Therapeutics ( PTGX ). The drug has also been submitted for approval to the European Medicines Agency (...
Kwangmoozaa/iStock via Getty Images Last Wednesday , Johnson & Johnson ( JNJ ) announced that the FDA had approved Icotyde, a once-daily oral peptide for the treatment of plaque psoriasis. This drug selectively blocks the interleukin-23 receptor (IL-23) and was a joint discovery with Protagonist Therapeutics ( PTGX ). The drug has also been submitted for approval to the European Medicines Agency (EMA), and the US launch is already underway. Upon learning this news, the market reacted by penalizing AbbVie ( ABBV ), with the stock trading approximately 5% lower since. AbbVie is the maker of an injectable IL-23 blocker named Skyrizi, which is the drugmaker's best-selling drug, achieving 2025 total sales of $17.6B . The 5% drop in AbbVie's stock represents a loss in market capitalization of approximately $28 billion (a $16/share drop times 1.77 billion shares outstanding). The clear winner of this development is Protagonist. The FDA approval triggered a $50M milestone payment from JNJ with potentially $580M in future milestones and a 6-10% royalty on sales of Icotyde. While the profit-sharing agreement limits upside to some extent, it also places the costs of commercialization with JNJ. Protagonist has additional commercialization catalysts that may be realized this year, specifically Rusfertide , a first-in-class hepcidin mimetic that targets red blood cell overproduction for the treatment of polycythemia vera (PV). The company has secured Priority Review with the FDA on the basis of the drug's Phase 3 VERIFY trial that met all primary and secondary endpoints. This drug is being developed with Takeda with a PDUFA date in Q3 2026 and potential commercialization thereafter. Protagonist's platform peptide technology presents the company with a strong pipeline of additional clinical candidates in obesity, hematology, and inflammation-related diseases. Analysts see the company achieving profitability this year from milestone payments, with more durable profitability by 2028...
Bitcoin Depot ( NASDAQ: BTM ) announced on Tuesday that Alex Holmes will be appointed as CEO and Chairman after Scott Buchanan stepped down as CEO, effective immediately. Holmes had spent over 16 years at MoneyGram International, including as CFO and COO, before serving as Chairman and CEO from 2016 to 2024, and had most recently been Executive Vice Chairman of United Texas Bank. He brings decades...
Bitcoin Depot ( NASDAQ: BTM ) announced on Tuesday that Alex Holmes will be appointed as CEO and Chairman after Scott Buchanan stepped down as CEO, effective immediately. Holmes had spent over 16 years at MoneyGram International, including as CFO and COO, before serving as Chairman and CEO from 2016 to 2024, and had most recently been Executive Vice Chairman of United Texas Bank. He brings decades of leadership in global payments and fintech, having led MoneyGram’s transformation into a modern global fintech operating in more than 200 countries. Brandon Mintz will transition from Executive Chair to a non-executive board member and is expected to serve as an advisor to the CEO. He built the company into one of the largest Bitcoin ATM networks and remains a long-term shareholder. More on Bitcoin Depot Bitcoin Depot Inc. (BTM) Q4 2025 Earnings Call Transcript Bitcoin Depot Inc. 2025 Q4 - Results - Earnings Call Presentation Bitcoin Depot ATMs suspended in Connecticut amid compliance failures Bitcoin Depot outlines 30%-40% 2026 revenue decline as it diversifies into fintech Seeking Alpha’s Quant Rating on Bitcoin Depot
Monty Rakusen/DigitalVision via Getty Images Investment Approach Fidelity® International Growth Fund is a diversified international equity strategy with a large-cap growth orientation. Our investment approach targets companies with multiyear structural growth prospects, high barriers to entry and attractive valuations based on our earnings forecasts. Investment ideas typically fall into three main...
Monty Rakusen/DigitalVision via Getty Images Investment Approach Fidelity® International Growth Fund is a diversified international equity strategy with a large-cap growth orientation. Our investment approach targets companies with multiyear structural growth prospects, high barriers to entry and attractive valuations based on our earnings forecasts. Investment ideas typically fall into three main categories: structurally attractive growth themes, where investors may be underestimating the durability of growth drivers and long-term earnings power; cyclically out-of-favor companies with limited competition and pricing power, where investors may be focusing on near-term cyclical concerns and discounting long-term prospects; and companies with strong earnings potential whose share prices have fallen due to macroeconomic events. We strive to uncover these companies through in-depth fundamental analysis, working in concert with Fidelity's global research team, with the goal of capturing market upside while limiting downside participation. Performance Review For the final quarter of 2025, the fund's Retail Class shares gained 0.29%, trailing the 1.88% advance of the benchmark MSCI EAFE Growth Index (Net MA). This result was affected by a downward fair-value pricing adjustment of 0.52 percentage points. Fair-value pricing is an adjustment process that attempts to best represent the value of the fund's securities as of the close of trading in U.S. markets, accounting for any major changes occurring after the close of foreign markets. Since index performance is not adjusted in a similar manner, this can be a source of performance deviation between the fund and its benchmark in any given time period. The impact of fair-value adjustments tends to smooth out over the long term, where performance comparisons remain quite favorable. International growth stocks extended their upward momentum the past three months, concluding 2025 up roughly 18%, with both developed and emerging ma...